844439-96-9

844439-96-9 structure
844439-96-9 structure
  • Name: Insulin degludec
  • Chemical Name: Insulin degludec
  • CAS Number: 844439-96-9
  • Molecular Formula: C274H408N64O81S6
  • Molecular Weight: 6103.97204
  • Catalog: API Hormone and endocrine-regulating drugs Pancreatic hormones and other blood sugar regulating drugs
  • Create Date: 2018-06-11 18:26:53
  • Modify Date: 2025-08-26 08:18:00
  • Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes[1][2].

Name Insulin degludec
Synonyms (1A-21A),(1B-29B)-Insulin (human), 29B-[N6-[N-(15-carboxy-1-oxopentadecyl)-L-γ-glutamyl]-L-lysine]-
N6,29B-[N-(15-carboxypentadecanoyl)-L-γ-glutamyl]-des-30B-L-threonine-human insulin
Insulin degludec
Description Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes[1][2].
Related Catalog
Target

IC50: 19.59 nM/L (insulin receptor)[2]

In Vitro Insulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC50 value of 19.59 nM/L[2]. Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells[2]. Western Blot Analysis[2] Cell Line: HL-1 cardiomyocytes Concentration: 200 nM Incubation Time: 0-60 min Result: Decreased the level of Akt phosphorylation after 5 and 10 min treatment.
In Vivo Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia[1]. Animal Model: Male Swiss mice with diabetes[1] Dosage: 5 U/kg Administration: Subcutaneous injection; 5 U/kg once daily for 30 days Result: Showed a fast response to insulin-induced hypoglycemia with a glycemic level at or slightly under 100 mg/dl after 60 min and this response effect can be abolished by cortisol. Diminished rates of glucose production and showed a low lactate production in livers. Increased the number of hepatocytes.
References

[1]. Bataglini C, et al. Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. J Appl Biomed. 2021 Dec;19(4):210-219.

[2]. Hartmann T, et al. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol. 2016 Jul

Molecular Formula C274H408N64O81S6
Molecular Weight 6103.97204
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.